NetworkNewsBreaks – Pressure BioSciences, Inc. (
Post# of 1354
(Total Views: 156)
Posted On: 12/13/2017 7:08:34 PM
NetworkNewsBreaks – Pressure BioSciences, Inc. (PBIO) Acquires All Assets of BaroFold, Inc.
Pressure BioSciences (OTCQB: PBIO) today reported the acquisition of all assets of BaroFold, Inc. The assets acquired include all patents, equipment, and intellectual property relating to BaroFold's PreEMT™ high-pressure protein refolding technology. A total of eight issued patents and several pending significantly enhances PBIO’s hold of intellectual property in high-pressure technologies. "In addition to the expected increase in revenue from instrument and consumable sales to customers developing biopharmaceutical manufacturing applications with the PreEMT technology, we expect the BaroFold acquisition to have positive effects on our services revenue as well. In this regard, we plan to continue the biologics contract research services program previously provided by Barofold. This entails extensive revenue-generating studies on the advantages of high-pressure processing in the manufacture of biopharmaceutical products using the patented PreEMT technology. We will also offer manufacturing-scale licenses to biopharmaceutical companies ready to take advantage of the PreEMT technology for more efficient production of their high-quality biological products. We believe such licenses have the potential to generate millions of dollars annually in royalty revenue,” Pressure Biosciences president and CEO Richard T. Schumacher stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO) today reported the acquisition of all assets of BaroFold, Inc. The assets acquired include all patents, equipment, and intellectual property relating to BaroFold's PreEMT™ high-pressure protein refolding technology. A total of eight issued patents and several pending significantly enhances PBIO’s hold of intellectual property in high-pressure technologies. "In addition to the expected increase in revenue from instrument and consumable sales to customers developing biopharmaceutical manufacturing applications with the PreEMT technology, we expect the BaroFold acquisition to have positive effects on our services revenue as well. In this regard, we plan to continue the biologics contract research services program previously provided by Barofold. This entails extensive revenue-generating studies on the advantages of high-pressure processing in the manufacture of biopharmaceutical products using the patented PreEMT technology. We will also offer manufacturing-scale licenses to biopharmaceutical companies ready to take advantage of the PreEMT technology for more efficient production of their high-quality biological products. We believe such licenses have the potential to generate millions of dollars annually in royalty revenue,” Pressure Biosciences president and CEO Richard T. Schumacher stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)